News for Eidos Therapeutics Inc (EIDX)

BridgeBio's acoramidis seems likely to secure approval in November, in the large market of ATTR-cardiomyopathy. Read more to see our analysis on BBIO stock.

- Phase 3 open-label, single-arm study conducted in Japan by BridgeBio licensing partner Alexion, AstraZeneca Rare Disease showed consistency with global ATTRibute-CM Phase III trial - No mortality...

(RTTNews) - Aeglea BioTherapeutics, Inc. (AGLE) announced its name change to Spyre Therapeutics, Inc. Effective as of market open on November 28, ...

Reaching US$ 4.56 Billion by 2033, AL Amyloidosis Therapeutics to be most Useful for Chemotherapy, commanding over 50% of all Applications. North American...

You might have Fridays off sooner than you think.

–Secured up to $750 million in non-dilutive debt financing in November 2021, extending BridgeBio’s financial runway into 2024 –Dosed first patient in...

/PRNewswire/ -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio or the Company), a commercial-stage biopharmaceutical company founded to discover, create,...

GuruFocus Article or News written by insider and the topic is about:

--Mit den Erlösen wird die Pipeline des Unternehmens an Zytokin-Immuntherapien der nächsten Generation vorangetrieben----Laura Shawver, Christine Siu...

--Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies----Laura Shawver, Christine Siu join as independent directors-- ...

GuruFocus Article or News written by insider and the topic is about:

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Ja...